Core Insights - The new HIV vaccine Lenacapavir is being introduced in South Africa, Swaziland, and Zambia, demonstrating a risk reduction of over 99.9% with biannual injections [1] Group 1: Vaccine Introduction and Impact - Lenacapavir is the first breakthrough HIV vaccine being promoted in several African countries [1] - The vaccine has shown to significantly reduce the risk of HIV transmission, with a 99.9% effectiveness rate [1] Group 2: HIV Statistics in Africa - Africa is the most affected region by HIV, with approximately 52% of the 40.8 million global HIV cases located in Eastern and Southern Africa [1] - In South Africa, one in five adults is HIV positive, while Zambia has around 1.4 million infections with 30,000 new cases annually [1] - Swaziland, with a population of only 1.2 million, has about 220,000 individuals living with HIV [1] Group 3: Vaccine Cost and Distribution - The cost for each individual to receive the vaccine is approximately $28,000 per year, with plans for broader distribution in South Africa next year [1] - The U.S. government plans to provide the vaccine manufacturer with the goal of supplying 2 million doses to high-prevalence countries over three years [1] - Zambia and Swaziland have received 1,000 doses through a U.S. aid program, but South Africa is excluded due to policy disagreements [1] Group 4: Future Availability and Pricing - An agreement between Unitaid, the Gates Foundation, and an Indian pharmaceutical company is expected to lead to generic versions of the vaccine being available in over 100 countries by 2027, priced at approximately $40 per year [1]